CN107373253A - 一种润肺饮料及制备方法和应用 - Google Patents
一种润肺饮料及制备方法和应用 Download PDFInfo
- Publication number
- CN107373253A CN107373253A CN201710664693.8A CN201710664693A CN107373253A CN 107373253 A CN107373253 A CN 107373253A CN 201710664693 A CN201710664693 A CN 201710664693A CN 107373253 A CN107373253 A CN 107373253A
- Authority
- CN
- China
- Prior art keywords
- parts
- root
- lung
- beverage
- moistening
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 235000013361 beverage Nutrition 0.000 title claims abstract description 21
- 238000002360 preparation method Methods 0.000 title claims description 6
- 241000723363 Clerodendrum Species 0.000 claims abstract description 10
- 241001412627 Adenophora liliifolia Species 0.000 claims abstract description 9
- 241000432824 Asparagus densiflorus Species 0.000 claims abstract description 9
- 235000013717 Houttuynia Nutrition 0.000 claims abstract description 9
- 240000000691 Houttuynia cordata Species 0.000 claims abstract description 9
- 241000608133 Platanthera Species 0.000 claims abstract description 9
- 235000001287 Guettarda speciosa Nutrition 0.000 claims abstract description 8
- 239000002994 raw material Substances 0.000 claims abstract description 5
- 244000061520 Angelica archangelica Species 0.000 claims abstract 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 25
- 239000000463 material Substances 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 239000012141 concentrate Substances 0.000 claims description 6
- 229930006000 Sucrose Natural products 0.000 claims description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 5
- 230000006837 decompression Effects 0.000 claims description 5
- 239000000706 filtrate Substances 0.000 claims description 5
- 239000005720 sucrose Substances 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 3
- 244000131316 Panax pseudoginseng Species 0.000 claims 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims 1
- 235000003140 Panax quinquefolius Nutrition 0.000 claims 1
- 235000008434 ginseng Nutrition 0.000 claims 1
- 210000004072 lung Anatomy 0.000 abstract description 22
- 208000005069 pulmonary fibrosis Diseases 0.000 abstract description 13
- 241000700159 Rattus Species 0.000 description 12
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 10
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 10
- 206010001889 Alveolitis Diseases 0.000 description 9
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- ISWRGOKTTBVCFA-UHFFFAOYSA-N pirfenidone Chemical compound C1=C(C)C=CC(=O)N1C1=CC=CC=C1 ISWRGOKTTBVCFA-UHFFFAOYSA-N 0.000 description 7
- 241000125175 Angelica Species 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 206010011732 Cyst Diseases 0.000 description 4
- 208000029523 Interstitial Lung disease Diseases 0.000 description 4
- 241001480233 Paragonimus Species 0.000 description 4
- 208000031513 cyst Diseases 0.000 description 4
- 238000003304 gavage Methods 0.000 description 4
- 229960003073 pirfenidone Drugs 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 201000003838 Idiopathic interstitial pneumonia Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 241000256856 Vespidae Species 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 230000001603 reducing effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N 1H-pyrrole Natural products C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 1
- 240000006995 Abutilon theophrasti Species 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 241000213006 Angelica dahurica Species 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 244000299452 Gouania lupuloides Species 0.000 description 1
- 235000000292 Gouania lupuloides Nutrition 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 208000007443 Neurasthenia Diseases 0.000 description 1
- 241000233855 Orchidaceae Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 241001515408 Platanthera minor Species 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 241001073567 Verbenaceae Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 206010061592 cardiac fibrillation Diseases 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 230000002600 fibrillogenic effect Effects 0.000 description 1
- 210000000630 fibrocyte Anatomy 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 210000000497 foam cell Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- -1 heat-clearing Substances 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 210000003456 pulmonary alveoli Anatomy 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 238000012764 semi-quantitative analysis Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 235000000891 standard diet Nutrition 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 210000002396 uvula Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/342—Adenophora
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/78—Saururaceae (Lizard's-tail family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/85—Verbenaceae (Verbena family)
- A61K36/855—Clerodendrum, e.g. glorybower
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8965—Asparagus, e.g. garden asparagus or asparagus fern
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明提供了一种润肺饮料，它由如下重量份数的原料制备得到：猪獠参20‑28份、鬼灯笼根18‑22份、鱼腥草20‑30份、天冬15‑25份、沙参30‑40份、白芷10‑20份、甘草5‑15份，本发明的功能是润肺，治疗肺纤维化。
Description
技术领域
本发明涉及饮料技术领域，具体涉及一种润肺饮料及制备方法和应用。
背景技术
肺纤维化是以成纤维细胞增殖及大量细胞外基质聚集并伴炎症损伤、组织结构破坏为特征的一大类肺疾病的终末期改变，也就是正常的肺泡组织被损坏后经过异常修复导致结构异常(疤痕形成)。绝大部分肺纤维化病人病因不明(特发性)，这组疾病称为特发性间质性肺炎(IIP)，是间质性肺病中一大类。而特发性间质性肺炎(IIP)中最常见的以肺纤维化病变为主要表现形式的疾病类型为特发性肺纤维化(IPF)，是一种能导致肺功能进行性丧失的严重的间质性肺疾病。肺纤维化严重影响人体呼吸功能，表现为干咳、进行性呼吸困难(自觉气不够用)，且随着病情和肺部损伤的加重，患者呼吸功能不断恶化。特发性肺纤维化发病率和死亡率逐年增加，诊断后的平均生存期仅2.8年，死亡率高于大多数肿瘤，被称为一种“类肿瘤疾病”。
发明内容
发明目的：为了解决上述问题，本发明的目的在于提供一种润肺饮料及制备方法和应用。
技术方案：本发明的目的是通过如下的方案实现的：
一种润肺饮料，它由如下重量份数的原料制备得到：猪獠参20-28份、鬼灯笼根18-22份、鱼腥草20-30份、天冬15-25份、沙参30-40份、白芷10-20份、甘草5-15份。
所述润肺饮料，它由如下重量份数的原料制备得到：猪獠参25份、鬼灯笼根20份、鱼腥草25份、天冬20份、沙参30-40份、白芷10-20份、甘草5-15份。
所述润肺饮料，制备方法包括如下步骤：取上述药材合并，加水煎煮两次，每次加水为药材重量的10倍量，煎煮2h，合并煎液，减压浓缩至65℃时相对密度为1.20的浸膏，加乙醇使含醇量的体积百分比达85％，搅拌，静置，过滤，滤液减压浓缩至65℃时相对密度为1.30，并回收乙醇，得浓缩液，加蔗糖，制成饮料。
所述润肺饮料在制备润肺饮料中的应用。
本发明中猪獠参为兰科植物小舌唇兰的全草，拉丁名：Platanthera minor(Miq.)Reichb.F.，养阴润肺，益气生津。用于咳痰带血，咽喉肿痛，病后体弱，神经衰弱，遗精，头晕。
鬼灯笼根为马鞭草科植物灯笼草的根或根皮，拉丁学名Clerodendronfortunatum L，具有清热、解毒、凉血、止痛等功效，主治感冒发热、赤痢、疮疥、瘰疬、肿痛等症状。，其余为药典品种。
有益效果：从中医理论看，本方中猪獠参、鬼灯笼根养阴润肺、益气生津、清热、解毒为君药，鱼腥草、天冬、沙参、白芷润肺化痰为臣药，甘草为佐使药，诸药相合，共奏养阴润肺作用，用于治疗肺纤维化。处方设计合理，配伍严谨，经长期的临床验证，疗效确切。组成为中药材，无毒副作用，价格便宜。
具体实施方式
以下通过实施例形式，对本发明的上述内容再作进一步的详细说明，但不应将此理解为本发明上述主题的范围仅限于以下的实例，凡基于本发明上述内容所实现的技术均属于本发明的范围。
实施例1：取猪獠参20份、鬼灯笼根22份、鱼腥草20份、天冬25份、沙参30份、白芷20份、甘草5份药材合并，加水煎煮两次，每次加水为药材重量的10倍量，煎煮2h，合并煎液，减压浓缩至65℃时相对密度为1.20的浸膏，加乙醇使含醇量的体积百分比达85％，搅拌，静置，过滤，滤液减压浓缩至65℃时相对密度为1.30，并回收乙醇，得浓缩液，加蔗糖，制成饮料。
实施例2：取猪獠参28份、鬼灯笼根18份、鱼腥草30份、天冬15份、沙参40份、白芷10份、甘草15份药材合并，加水煎煮两次，每次加水为药材重量的10倍量，煎煮2h，合并煎液，减压浓缩至65℃时相对密度为1.20的浸膏，加乙醇使含醇量的体积百分比达85％，搅拌，静置，过滤，滤液减压浓缩至65℃时相对密度为1.30，并回收乙醇，得浓缩液，加蔗糖，制成饮料。
实施例3：取猪獠参25份、鬼灯笼根20份、鱼腥草25份、天冬20份、沙参30-40份、白芷10-20份、甘草5-15份药材合并，加水煎煮两次，每次加水为药材重量的10倍量，煎煮2h，合并煎液，减压浓缩至65℃时相对密度为1.20的浸膏，加乙醇使含醇量的体积百分比达85％，搅拌，静置，过滤，滤液减压浓缩至65℃时相对密度为1.30，并回收乙醇，得浓缩液，加蔗糖，制成饮料。
实施例4：本发明对肺纤维化的影响
试验对象：选取健康雄性SD大鼠50只，体重为260-280g，由南京正宽医药科技有限公司实验动物中心提供。
试验材料：实施例1制备的润肺饮料，吡非尼酮胶囊，购于北京康蒂尼药业有限公司，国药准字H201333760
特发性肺纤维化动物模型建立：从50只大鼠中随机挑选10只作为对照组大鼠，剩余的大鼠腹腔注射3％浓度为30mg/kg的戊巴比妥钠，麻醉后仰卧固定鼠台，颈部备皮后常规消毒铺巾，切开皮肤后逐层钝性分离暴露气管，以1mL的注射器斜行刺入气管内，向肺内快速注射博来霉素溶液0.2-0.3m1，立即竖起鼠板，左右摇晃2min后，再次消毒皮肤缝合伤口。
试验方法：将建模成功的40只大鼠随机分为模型组、吡非尼酮胶囊组、实施例1组，各组给药量如下：对照组：灌胃等体积的生理盐水；模型组：灌胃等体积的生理盐水；吡非尼酮组：灌胃10mg/kg的吡非尼酮；实施例1组：灌胃l0ml/kg的实施例1制备的饮料；试验期间大鼠自由饮水，进食(标准饮食)。每周测量大鼠体重一次。于试验开始给药后的第4周处死大鼠。采用股动脉放血法处死大鼠，戊巴比妥钠麻醉后，将大鼠仰卧固定于鼠台上，开胸显露心肺，取下肺脏后用生理盐水反复清洗，用电子天平称量体重和肺重，计算肺系数(肺脏重量/体重X 1000，使用试剂盒检测大鼠的血清层粘连蛋白((LN)含量。接着，使用4％甲醛固定右上肺、左下肺，常规脱水包埋，制成Sum厚石蜡切片，以备HE染色。
特发性肺纤维化的病理半定量分析，肺泡炎和肺纤维化程度的评判标准如下：(1)肺泡炎分级：0级：无肺泡炎；1级：轻度肺泡炎，病变范围局限在全肺20％以下；2级：中度肺泡炎，病变范围占全肺20％-50％；3级：弥漫性肺泡炎，病变范围大于50％。(2)肺间质纤维化分级：0级：无肺间质纤维化；1级：轻度肺间质纤维化，病变范围局限在全肺20％以下；2级：中度肺间质纤维化，病变范围占全肺20％-50％；3级：重度肺间质纤维化，病变范围大于50％，肺泡融合，肺实质结构紊乱。利用显微图像分析系统，对病理切片进行肺泡炎和纤维化程度自动测量，将肺组织HE染色病理切片分成以下三个区域进行分析：无染区：为肺泡腔所占面积；深染区：为细胞核所占面积；浅染区：为肺间质纤维结缔组织所占面积。肺泡炎和肺纤维化的程度可由以上三个区域所占面积的不同进行确定。肺泡炎时肺间质炎性细胞浸润增加，表现为深染区面积增加，而肺间质纤维化时，肺泡大多塌陷或消失，间质出现大量胶原纤维，表现为无染区面积减少，浅染区面积增加。用深染区代表细胞核所占面积，即肺泡炎症面积，浅染区代表纤维结缔组织与胶原纤维所占面积，无染区代表肺泡腔面积。将病理切片置于图像分析仪显微镜下，在lOx视野下，每张切片由左到右，由上到下依次选取10个视野进行图像分析。
试验结果：本发明对特发性肺纤维化模型大鼠肺系数和LN含量的影响。
| 组别 | 肺系数 | LN含量(pg/mL) |
| 对照组 | 0.45±0.03 | 76.54±9.57 |
| 模型组 | 0.59±0.05 | 142.78±18.21 |
| 吡非尼酮胶囊组 | 0.43±0.06* | 86.12±12.46* |
| 实施例1组 | 0.42±0.05* | 90.63±14.98* |
与模型组比较*p<0.05
可知，与模型组相比，吡非尼酮组和实施例1组均可以显著的降低特发性肺纤维化模型的肺系数，而且实施例1组的降低效果与吡非尼酮组接近，同时，实施例1组也可以显著降低特发性肺纤维化模型的LN含量，说明本发明对特发性肺纤维化具有显著的改善作用。
本发明对肺组织病理的影响：与对照组相比，模型组大鼠呈现重度肺泡炎，局部有较多出血灶，肺泡隔增宽，炎性细胞浸润，巨噬细胞活化明显；体积增大，细胞内含有大量颗粒，大部分巨噬细胞呈泡沫样改变；片状聚集活化的成纤维细胞紧密相邻，肺泡隔及炎症区域见片状增生的胶原纤维，纤维化程度明显增加。与模型组相比，吡非尼酮组和实施例1组均可显著的改善特发性肺纤维化模型的肺泡炎、巨噬细胞泡沫样改变、纤维细胞活化和胶原纤维增生等症状，说明本发明对特发性肺纤维化具有显著的改善作用。
Claims (4)
1.一种润肺饮料，其特征在于，它由如下重量份数的原料制备得到：猪獠参20-28份、鬼灯笼根18-22份、鱼腥草20-30份、天冬15-25份、沙参30-40份、白芷10-20份、甘草5-15份。
2.如权利要求1所述润肺饮料，其特征在于，它由如下重量份数的原料制备得到：猪獠参25份、鬼灯笼根20份、鱼腥草25份、天冬20份、沙参30-40份、白芷10-20份、甘草5-15份。
3.如权利要求1所述润肺饮料，其特征在于，制备方法包括如下步骤：取上述药材合并，加水煎煮两次，每次加水为药材重量的10倍量，煎煮2h，合并煎液，减压浓缩至65℃时相对密度为1.20的浸膏，加乙醇使含醇量的体积百分比达85％，搅拌，静置，过滤，滤液减压浓缩至65℃时相对密度为1.30，并回收乙醇，得浓缩液，加蔗糖，制成饮料。
4.如权利要求1所述润肺饮料在润肺饮料中的应用。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710664693.8A CN107373253A (zh) | 2017-08-07 | 2017-08-07 | 一种润肺饮料及制备方法和应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710664693.8A CN107373253A (zh) | 2017-08-07 | 2017-08-07 | 一种润肺饮料及制备方法和应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107373253A true CN107373253A (zh) | 2017-11-24 |
Family
ID=60343949
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710664693.8A Withdrawn CN107373253A (zh) | 2017-08-07 | 2017-08-07 | 一种润肺饮料及制备方法和应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107373253A (zh) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104707126A (zh) * | 2015-04-10 | 2015-06-17 | 山东三生新材料科技有限公司 | 一种治疗肺炎链球菌感染性肺炎的药物及制备方法 |
| CN106492047A (zh) * | 2016-12-30 | 2017-03-15 | 毛永 | 一种治疗风热犯肺证的中药 |
-
2017
- 2017-08-07 CN CN201710664693.8A patent/CN107373253A/zh not_active Withdrawn
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104707126A (zh) * | 2015-04-10 | 2015-06-17 | 山东三生新材料科技有限公司 | 一种治疗肺炎链球菌感染性肺炎的药物及制备方法 |
| CN106492047A (zh) * | 2016-12-30 | 2017-03-15 | 毛永 | 一种治疗风热犯肺证的中药 |
Non-Patent Citations (2)
| Title |
|---|
| 于新编著: "《野菜食用与药用手册》", 30 June 2012, 中国纺织出版社 * |
| 李红主编: "《中西医结合呼吸病学》", 31 May 2014, 甘肃科学技术出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20080233220A1 (en) | Further Medical Use Of A Botanical Drug Or Dietary Supplement | |
| CN106420656B (zh) | 一种金莲花泡腾片及其制备方法 | |
| CN103142842A (zh) | 一种治疗糖尿病的中药 | |
| CN103721075B (zh) | 一种用于妇产科术后的中药及其制备方法 | |
| CN107373253A (zh) | 一种润肺饮料及制备方法和应用 | |
| CN107596110B (zh) | 一种治疗特发性肺纤维化的中药组合物及其用途 | |
| CN109247528A (zh) | 一种用于缓解甲状腺结节及甲减功效的组合物及其应用 | |
| CN110038066A (zh) | 一种治疗慢性疲劳综合征的中药组合物及其制备方法 | |
| CN108578487A (zh) | 治疗寻常型银屑病的药物组合物及制剂和制备应用 | |
| CN103536806B (zh) | 一种治疗酒精性心肌病的药物组合物 | |
| CN106310017A (zh) | 一种治疗弥漫性肺间质纤维化肺肾气虚证的中药颗粒 | |
| CN102908607B (zh) | 用于治疗慢性单纯性鼻炎的外用中药及其制备方法 | |
| CN105147915A (zh) | 益肝宝软胶囊及制备工艺 | |
| CN104800662A (zh) | 一种治疗老年心力衰竭的中药及制备方法 | |
| CN101543574A (zh) | 一种治疗肺间质纤维化的中药组合物 | |
| CN103800698B (zh) | 一种治疗器官纤维化的药物组合物及其制备方法和用途 | |
| CN110101800A (zh) | 一种治疗恶性胸腔积液中药组合物及其应用 | |
| CN108310195A (zh) | 一种治疗特发性肺纤维化的中药组合物及其制备方法和应用 | |
| CN110301641A (zh) | 一种辅助保护胃黏膜的保健食品 | |
| JP2005533797A (ja) | 薬物中毒症治療用ｙｉａｎ煎出物 | |
| CN110478406A (zh) | 一种具有缓解甲状腺功能减退功效的中药组合物及其制备方法、应用和产品 | |
| CN104127544B (zh) | 四数九里香及其提取物在制备药物中的应用 | |
| CN104688939B (zh) | 治疗慢性阻塞性肺病的中药组合物及其制备方法 | |
| CN103948778A (zh) | 一种用于更年期综合症的药物及颗粒 | |
| CN104740428B (zh) | 一种复方红衣补血药物制剂及其应用和检测方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20171124 |
|
| WW01 | Invention patent application withdrawn after publication |